BIOGEN (BIIB)

We think the company has a above average capital gains return. The comèany has taken a lot of debt, and we belive that that debt will be used soon to make an acquisition. Potential target is Shire Pharma .

Related Ideas

IMPORTANT:
Please remind yourself that this is just my personal view on the market. My analysis should NOT serve as any recommendation to buy or to sell.
If you find useful my analysis, please hit the LIKE button and follow me.